Serum neurofilament light chain and glial fibrillary acidic protein in AQP4‐IgG‐seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study

2021 ◽  
Author(s):  
Chunxin Liu ◽  
Yaxin Lu ◽  
Jingqi Wang ◽  
Yanyu Chang ◽  
Yuge Wang ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cohort Study ◽  
Glial Fibrillary Acidic Protein ◽  
Neuromyelitis Optica ◽  
Light Chain ◽  
Acidic Protein ◽  
Neuromyelitis Optica Spectrum Disorders ◽  
Neurofilament Light Chain ◽  
Neurofilament Light ◽  
Spectrum Disorders

Area postrema syndrome: Another feature of anti-GFAP encephalomyelitis

2019 ◽  
Vol 26 (2) ◽  
pp. 253-255 ◽  
Author(s):  
Jonathan Ciron ◽  
Fanny Sourdrille ◽  
Damien Biotti ◽  
Thierry Tchoumi ◽  
Anne Ruiz ◽  
...  
Keyword(s):  
Glial Fibrillary Acidic Protein ◽  
Neuromyelitis Optica ◽  
Area Postrema ◽  
Acidic Protein ◽  
Neuromyelitis Optica Spectrum Disorders ◽  
Spectrum Disorders

Anti–Glial fibrillary acidic protein (GFAP) encephalomyelitis is a recently described entity and while the spectrum of this disease has been explored, further research is needed to fully describe its phenotype. Area postrema syndrome (APS) is usually associated with neuromyelitis optica spectrum disorders (NMOSDs), whereas no case of APS has been previously reported with anti-GFAP encephalomyelitis. In this article, we report a case of APS in a 41-year-old woman in the context of anti-GFAP encephalomyelitis. This case was not associated with additional anti-AQP4 IgG and therefore extends the clinico-radiological spectrum of anti-GFAP encephalomyelitis.

Absence of attack-independent neuroaxonal injury in MOG antibody-associated disease: Longitudinal assessment of serum neurofilament light chain

2021 ◽  
pp. 135245852110637
Author(s):  
Jae-Won Hyun ◽  
So Yeon Kim ◽  
Yeseul Kim ◽  
Na Young Park ◽  
Ki Hoon Kim ◽  
...  
Keyword(s):  
Glial Fibrillary Acidic Protein ◽  
Single Molecule ◽  
Light Chain ◽  
Myelin Oligodendrocyte Glycoprotein ◽  
Acidic Protein ◽  
Healthy Controls ◽  
Longitudinal Assessment ◽  
Neurofilament Light Chain ◽  
Neurofilament Light

To evaluate the occurrence of attack-independent neuroaxonal and astrocytic damage in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP) levels were longitudinally measured in 102 sera using a single-molecule array assay. Sera from 15 adults with relapsing MOGAD with available longitudinal samples for the median 24-month follow-up and 26 age-/sex-matched healthy controls were analyzed. sNfL levels were significantly elevated in all clinical attacks, where the levels decreased below or close to cut-off value within 6 months after attacks. sNfL levels were consistently low during inter-attack periods. In contrast, sGFAP levels did not increase in most clinical attacks and remained low during follow-up. Significant neuroaxonal damage was observed at clinical attacks, while attack-independent neuroaxonal and astrocytic injury was absent in MOGAD.

Neurofilament light chain levels in pregnant multiple sclerosis patients: a prospective cohort study

2019 ◽  
Vol 26 (9) ◽  
pp. 1200-1204 ◽  
Author(s):  
J. P. Cuello ◽  
M. L. Martínez Ginés ◽  
J. Kuhle ◽  
J. M. García Domínguez ◽  
A. Lozano Ros ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cohort Study ◽  
Prospective Cohort Study ◽  
Light Chain ◽  
Prospective Cohort ◽  
Neurofilament Light Chain ◽  
Neurofilament Light ◽  
Multiple Sclerosis Patients

scholarly journals Plasma neurofilament light chain and glial fibrillary acidic protein predict stroke in CADASIL

2020 ◽  
Author(s):  
Chen Chih-Hao ◽  
Yu-Wen Cheng ◽  
Ya-Fang Chen ◽  
Sung-Chun Tang ◽  
Jiann-Shing Jeng
Keyword(s):  
Glial Fibrillary Acidic Protein ◽  
Light Chain ◽  
Odds Ratio ◽  
Acidic Protein ◽  
White Matter Hyperintensity ◽  
Stroke Recurrence ◽  
Neurofilament Light Chain ◽  
Neurofilament Light ◽  
Plasma Biomarkers

Abstract Background Stroke remains the most cumbersome disease burden in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). This study aimed to investigate whether plasma biomarkers can reflect disease severity and predict stroke recurrence in CADASIL patients. Methods Sixty-three CADASIL patients (mean age 58.9±9.3 years old, male 63%) from a multicenter registry and 17 controls were recruited. Plasma biomarkers, namely neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), tau, and ubiquitin carboxy-terminal hydrolase L1 (UCHL1), were measured using an ultra-sensitive single molecule array at baseline. Neuroimaging markers assessed included the Fazekas scale of white matter hyperintensity, numbers of lacunes and cerebral microbleeds (CMBs). Cox proportional hazards regression models were applied to calculate the hazard ratio (HR) of plasma biomarkers at baseline for predicting incident stroke during follow-up. Results Plasma NfL, GFAP, and UCHL1 levels were significantly elevated in the CADASIL patients than in the controls. Among the CADASIL patients, both plasma NfL and GFAP levels positively correlated with the numbers of CMBs (r = 0.32 and r = 0.37, respectively; both p < 0.05). Higher plasma levels of NfL and GFAP were associated with any stroke (odds ratio 2.02, 95% confidence interval [CI] 1.06–3.87) and ICH (odds ratio 2.06, 95% CI 1.26–3.35) at baseline, respectively. Within a mean follow-up period of 3.1 Common.EditSubmissionSteps.Transform.EquationText 2.1 years, 10 patients (16%) had incident stroke and 6 of them were ICH. Higher baseline NfL (HR 1.93, 95% CI 1.19–3.13) predicted any incident stroke, whereas higher GFAP (HR 2.80, 95% CI 1.21–6.53) predicted incident ICH. Conclusions In CADASIL patients, plasma NfL can be a promising biomarker for monitoring incident stroke, whereas GFAP may have a role in cerebral hemorrhage.

scholarly journals Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia

2021 ◽  
Vol 10 (1) ◽  
Author(s):  
Nuole Zhu ◽  
Miguel Santos-Santos ◽  
Ignacio Illán-Gala ◽  
Victor Montal ◽  
Teresa Estellés ◽  
...  
Keyword(s):  
Glial Fibrillary Acidic Protein ◽  
Cognitive Decline ◽  
Frontotemporal Dementia ◽  
Cortical Thickness ◽  
Light Chain ◽  
Diagnostic Performance ◽  
Acidic Protein ◽  
Neurofilament Light Chain ◽  
Neurofilament Light

Abstract Background Astrocytes play an essential role in neuroinflammation and are involved in the pathogenesis of neurodenegerative diseases. Studies of glial fibrillary acidic protein (GFAP), an astrocytic damage marker, may help advance our understanding of different neurodegenerative diseases. In this study, we investigated the diagnostic performance of plasma GFAP (pGFAP), plasma neurofilament light chain (pNfL) and their combination for frontotemporal dementia (FTD) and Alzheimer’s disease (AD) and their clinical utility in predicting disease progression. Methods pGFAP and pNfL concentrations were measured in 72 FTD, 56 AD and 83 cognitively normal (CN) participants using the Single Molecule Array technology. Of the 211 participants, 199 underwent cerebrospinal (CSF) analysis and 122 had magnetic resonance imaging. We compared cross-sectional biomarker levels between groups, studied their diagnostic performance and assessed correlation between CSF biomarkers, cognitive performance and cortical thickness. The prognostic performance was investigated, analyzing cognitive decline  through group comparisons by tertile. Results Unlike pNfL, which was increased similarly in both clinical groups, pGFAP was increased in FTD but lower than in AD (all P < 0.01). Combination of both plasma markers improved the diagnostic performance to discriminate FTD from AD (area under the curve [AUC]: combination 0.78; pGFAP 0.7; pNfL 0.61, all P < 0.05). In FTD, pGFAP correlated with cognition, CSF and plasma NfL, and cortical thickness (all P < 0.05). The higher tertile of pGFAP was associated with greater change in MMSE score and poor cognitive outcome during follow-up both in FTD (1.40 points annually, hazard ratio [HR] 3.82, P < 0.005) and in AD (1.20 points annually, HR 2.26, P < 0.005). Conclusions pGFAP and pNfL levels differ in FTD and AD, and their combination is useful for distinguishing between the two diseases. pGFAP could also be used to track disease severity and predict greater cognitive decline during follow-up in patients with FTD.

scholarly journals Plasma neurofilament light chain and glial fibrillary acidic protein predict stroke in CADASIL

2020 ◽  
Author(s):  
Chih-Hao Chen ◽  
Yu-Wen Cheng ◽  
Ya-Fang Chen ◽  
Sung-Chun Tang ◽  
Jiann-Shing Jeng
Keyword(s):  
Glial Fibrillary Acidic Protein ◽  
Light Chain ◽  
Odds Ratio ◽  
Acidic Protein ◽  
White Matter Hyperintensity ◽  
Stroke Recurrence ◽  
Neurofilament Light Chain ◽  
Neurofilament Light ◽  
Plasma Biomarkers

Abstract Background Stroke remains the most cumbersome disease burden in patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). This study aimed to investigate whether plasma biomarkers can reflect disease severity and predict stroke recurrence in CADASIL patients. Methods Sixty-three CADASIL patients (mean age 58.9±9.3 years old, male 63%) from a multicenter registry and 17 controls were recruited. Plasma biomarkers, namely neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), tau, and ubiquitin carboxy-terminal hydrolase L1 (UCHL1), were measured using an ultra-sensitive single molecule array at baseline. Neuroimaging markers assessed included the Fazekas scale of white matter hyperintensity, numbers of lacunes and cerebral microbleeds (CMBs). Cox proportional hazards regression models were applied to calculate the hazard ratio (HR) of plasma biomarkers at baseline for predicting incident stroke during follow-up. Results Plasma NfL, GFAP, and UCHL1 levels were significantly elevated in the CADASIL patients than in the controls. Among the CADASIL patients, both plasma NfL and GFAP levels positively correlated with the numbers of CMBs (r = 0.32 and r = 0.37, respectively; both p < 0.05). Higher plasma levels of NfL and GFAP were associated with any stroke (odds ratio 2.02, 95% confidence interval [CI] 1.06–3.87) and ICH (odds ratio 2.06, 95% CI 1.26–3.35) at baseline, respectively. Within a mean follow-up period of 3.1 Common.EditSubmissionSteps.Transform.EquationText 2.1 years, 10 patients (16%) had incident stroke and 6 of them were ICH. Higher baseline NfL (HR 1.93, 95% CI 1.19–3.13) predicted any incident stroke, whereas higher GFAP (HR 2.80, 95% CI 1.21–6.53) predicted incident ICH. Conclusions In CADASIL patients, plasma NfL can be a promising biomarker for monitoring incident stroke, whereas GFAP may have a role in cerebral hemorrhage.

Sign in / Sign up

Export Citation Format

Share Document